The role of salivary function in modulating chemotherapy-induced oropharyngeal mucositis: A review of the literature

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics

Volumn 94, Issue 1, 2002, Pages 39-44

  Epstein, Joel B ^a,b,c   Tsang, Andrew H F ^a,b,d   Warkentin, Dawn ^a,b   Ship, Jonathan A ^d,e  

^a VANCOUVER HOSPITAL AND HEALTH SCIENCES CENTRE   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF WASHINGTON   (United States)

^d Vancouver Hospital and Health Sciences Centre ^*  (Canada)

^e NEW YORK UNIVERSITY COLLEGE OF DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; METHOTREXATE;

ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; HUMAN; MOUTH MUCOSA; PHYSIOLOGY; REVIEW; SALIVA; STOMATITIS;

ANIMALS; ANTINEOPLASTIC AGENTS; DOXORUBICIN; HUMANS; METHOTREXATE; MOUTH MUCOSA; SALIVA; STOMATITIS;

EID: 0036652764     PISSN: 10792104     EISSN: None     Source Type: Journal    
DOI: 10.1067/moe.2002.126018     Document Type: Article

References (34)

1. Epstein JB, Schubert MM. Oral mucositis in myelosuppressive cancer therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999;88:273-6.
2. Bellm LA, Epstein JB, Rose-Ped A, Martin P, Fuchs HJ. Patient reports of complications of bone marrow transplantation. Support Care Cancer 2000;8:33-9.
3. Sonis ST. Mucositis as a biologic process: a new hypothesis for the development of chemotherapy-induced mucositis. Oral Oncol 1998;34:39-43.
4. Ishii E, Yamada S, Higuchi S, Honjo, T, Igarashi H, Kanemitsu S, et al. Oral mucositis and salivary methotrexate concentration in intermediate-dose methotrexate therapy for children with acute lymphoblastic leukemia. Med Pediatr Oncol 1989;17:429-32.
5. Oliff A, Bleyer WA, Poplack DG. Methotrexate-induced oral mucositis and salivary methotrexate concentrations. Cancer Chemother Pharmacol 1979;2:225-6.
6. Bressolle F, Jacquet JM, Galtier M, Joudan J, Donadio D, Rossi JF. Doxorubicin and doxorubicinol plasma concentrations and excretion in parotid saliva. Cancer Chemother Pharmacol 1992;30:215-8.
7. McEvoy GK, editor. American Hospital Formulary Service. Bethesda (MD): American Society of Health-System Pharmacists, Inc; 1998. pp 747-49, 779-87, 792-7.
8. Slavik M, Wu J, Riley C. Salivary excretion of anticancer drugs. Ann NY Acad Sci 1993;694:319.
9. Svojanovsky SR, Egodage KL, Wu J, Slavik M, Wilson GS. High sensitivity ELISA determination of taxol in various human biological fluids. J Pharm Biomed Anal 1999;20:549-55.
10. Barrett AP. Clinical characteristics and mechanisms involved in chemotherapy-induced oral ulceration. Oral Surg Oral Med Oral Pathol 1987;63:424-8.
11. Symonds RP. Treatment-induced mucositis: an old problem with new remedies. Br J Cancer 1998;77:1689-95.
12. Milano G, Thyss A, Santini J, Frenay M, Francois E, Schneider M, Demard F. Salivary passage of 5-fluorouracil during continuous infusion. Cancer Chemother Pharmacol 1989;24:197-9.
13. van Warmerdam LJ, van Tellingen O, Huinink WE, Rodenhuis S, Maes RA, Bijnen JH. Monitoring carboplatin concentrations in saliva: a replacement for plasma ultrafiltrate measurements? Ther Drug Monit 1995;17:465-70.
14. Oblon DJ, Paul SR, Oblon MB, Malik S. Propantheline protects the oral mucosa after high-dose ifosfamide, carboplatin, etoposide and autologous stem cell transplantation. Bone Marrow Transplant 1997;20:961-3.
15. Brown RA, Herzig RH, Wolf SN, Frei-Lahr D, Pineiro L, Bolwell BJ, et al. High-dose etoposide and cyclophosphamide without bone marrow transplantation for resistant hematology malignancies. Blood 1990;76:473-9.
16. Ahmed T, Engelking C, Szalyga J, Helson L, Coombe N, Cook P, et al. Propantheline prevention of mucositis from etoposide. Bone Marrow Transplant 1993;12:131-2.
17. Loprinzi CL, Foote RL, Michalak J. Alleviation of cytotoxic therapy-induced normal tissue damage. Semin Oncol 1995;22:95-7.
18. Rocke LK, Loprinzi CL, Lee JK, Kunselman SJ, Iverson RK, Finck G, et al. A randomized clinical trial of two different durations of oral cryotherapy for prevention of 5-fluorouracil-related stomatitis. Cancer 1993;72:2234-8.
19. Sylvester RK, Lobell MK, Teresi ME. Excretion of hydroxyurea into milk. Cancer 1987;60:2177-8.
20. McCarthy GM, Awde JD, Ghandi H, Vincent M, Kocha WI. Risk factors associated with mucositis in cancer patients receiving 5-fluorouracil. Oral Oncol 1998;34:484-90.
21. Harrison T, Bigler L, Tucci M, Pratt L, Malamud F, Thigpen JT, et al. Salivary sIgA concentrations and stimulated whole saliva flow rates among women undergoing chemotherapy for breast cancer: an exploratory study. Spec Care Dent 1998;18:109-12.
22. Dens F, Boogaerts M, Boute P, Dederek D, Demuynck H, Vinckier F, et al. Quantitative determination of immunological components of salivary gland secretion in transplant recipients. Bone Marrow Transplant 1996;17:421-3.
23. Jankovic L, Jelic S, Filipovic-Ljeskovic I, Ristovic Z. Salivary immunoglobulins in cancer patients with chemotherapy-related oral mucosa damage. Eur J Cancer B Oral Oncol 1995;31:160-5.
24. Challacombe SJ. Passage of serum immunoglobulins into the oral cavity. In Lehner T, Cimansoni G, editors. The borderland between caries and periodontal disease II. London: Academic Press; 1980. p 31.
25. Spijkervet FK, Van Saene HK, Van Saene JJ, Panders AK, Vermey A, Mehta DM, et al. Effect of selective elimination of the oral flora on mucositis in irradiated head and neck cancer patients. J Surg Oncol 1991;46:167-33.
26. Symonds RP, McIlroy P, Khorrami J, Paul J, Pyper E, Alcock SR, et al. The reduction of radiation mucositis by selective decontamination antibiotic pastilles: a placebo-controlled double-blind trial. Br J Cancer 1996;74:312-7.
27. Mansson-Rahemtulla B, Techanitiswad T, Rahemtulla F, McMillan TO, Bradley EL, Wahlin YB. Analyses of salivary components in leukemia patients receiving chemotherapy. Oral Surg Oral Med Oral Pathol 1992;73:35-46.
28. Wolff A, Moreira JE, Marmary Y, Fox PC. Lack of acute effects of methotrexate on rat parotid salivary gland function. Arch Oral Biol 1989;2:109-15.
29. McBride RK, Siegel IA. Effect of methotrexate on protein and amylase secretion by rat parotid and submandibular glands. Arch Oral Biol 1988;33:245-9.
30. McBride RK, Harper C, Siegel IA. Methotrexate-induced changes in rat parotid and submandibular gland function. J Dent Res 1987;66:1445-8.
31. Johns DG, Rutherford LD, Leighton PC, Vogel CL. Secretion of methotrexate into human milk. Am J Obstet Gynecol 1972;112:978-80.
32. Wiernik PH, Duncan JH. Cyclophosphamide in human milk [letter]. Lancet 1971;1:912.
33. Egan PC, Costanza ME, Dodion P, Egorin MI, Bachur NR. Doxorubicin and cisplatin excretion into human milk. Cancer Treat Rep 1985;69:1387-9.
34. Baum BJ, Bodner L, Fox PC, Izutsu KT, Pizzo PA, Wright WE. Therapy-induced dysfunction of salivary glands: implications for oral health. Spec Care Dentist 1985;5:274-7.